Sunday, Summit Therapeutics Inc. (NASDAQ:SMMT) released data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab conducted in China, sponsored by collaboration partner Akeso, Inc. The data was presented at the International Association for the Study of Lung Cancer’s 2024 World Conference on Lung Cancer. The trial evaluated monotherapy ivonescimab against monotherapy Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in patients with locally advanced or metastatic non-small cell lung cancer whose tumors have positive PD-L1 expression. Ivonescimab monotherapy demonstrated a…
